Abstract
This article reviews if local immunosuppression of atopic dermatitis is associated with an increased risk of cancer - as implicated by a warning issued by the FDA and EMEA health authorities because systemic immunosuppression of transplanted patients leads to a significant increase of non-melanoma skin cancer and lymphoma. So far, no studies support that the use of topical immunosuppression increases the risk of local or systemic cancer.
MeSH terms
-
Administration, Topical
-
Adult
-
Child
-
Dermatitis, Atopic / drug therapy*
-
Dermatitis, Atopic / immunology
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Lymphoma / chemically induced
-
Risk Factors
-
Skin Neoplasms / chemically induced
-
Tacrolimus / administration & dosage
-
Tacrolimus / adverse effects
-
Tacrolimus / analogs & derivatives*
Substances
-
Immunosuppressive Agents
-
pimecrolimus
-
Tacrolimus